Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
WOK · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortWORK Medical Technology Group LTD is loss-making, generates cash and carries moderate debt, with revenue shrinking (−14.4% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | – | n/a |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -10.9% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -6.8% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.71× | 76/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.35× | 92/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 49.9% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 4 | 37/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 4 | 50/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 3 | 0/100 |
| Revenue growth volatility | 9.5% | 76/100 |
| Operating margin volatility | – | n/a |
Weight in the score: 20%
| Revenue growth, 3-year average | -20.6% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 20 | 14 | 12 | 9.8 |
| Gross profit | 4.4 | 4.1 | 2.9 | 2.3 |
| Research & development | 0.2 | 0.3 | 0.3 | 0.4 |
| Interest expense | 0.4 | 0.4 | 0.6 | 0.5 |
| Pre-tax income | 1.1 | 0.1 | (3.7) | (1.1) |
| Income tax | 0.2 | 0 | (0.1) | 0.1 |
| Net income | 0.9 | 0.1 | (3.5) | (1.1) |
| Diluted EPS | $0.07 | $0.01 | −$0.27 | −$0.04 |
| Diluted shares (millions) | 13 | 13 | 13 | 29 |
Not computed: a required balance-sheet item is missing.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Sep 30, 2025 · Data updated Jan 30, 2026